jurpsy schreef op 24 juli 2017 13:29:
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration[Docket No. FDA-2017-N-3068]
Patient-Focused Drug Development for Hereditary Angioedema; Public Meeting; Request for Comments.
SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is announcing a
public meeting and an opportunity for public comment on "Patient-Focused Drug Development
for Hereditary Angioedema." Patient-Focused Drug Development is part of FDA’s performance
commitment under the fifth authorization of the Prescription Drug User Fee Act (PDUFA V).
The public meeting is intended to allow FDA to obtain patients' perspectives on the impact of
hereditary angioedema (HAE) on daily life. FDA also is seeking patients' views on treatment
approaches for HAE.
DATES: The public meeting will be held on September 25, 2017, from 9 a.m. to 3 p.m.
Registration to attend must be received by August 10, 2017. Submit either electronic or written
comments on the public meeting by November 20, 2017.
Hopelijk verslapen en verknallen ze dit niet!!
PH. zal aanwezig zijn.
jurps.